Tedatioxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tedatioxetine
Tedatioxetine.svg
Tedatioxetine ball-and-stick model.png
Systematic (IUPAC) name
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
Clinical data
Legal status
  • Investigational
Identifiers
CAS Registry Number 508233-95-2 YesY
ATC code None
PubChem CID: 9878913
ChemSpider 8054590 YesY
KEGG D10170 N
Synonyms Lu AA24530; Lu-AA-24530
Chemical data
Formula C18H21NS
Molecular mass 283.43 g/mol
 N (what is this?)  (verify)

Tedatioxetine (Lu AA24530) is an antidepressant which is or was under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD).[1][2] It is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.[3][4][5][6] As of 2009, it was in phase II clinical trials,[6] but there have been no updates since then, and it is no longer displayed on Lundbeck's product pipeline.[1]

See also[edit]

References[edit]

External links[edit]